Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
3
×
boston
cancer
clinical trials
fda
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
beam therapeutics
biotech week boston
boston university
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
broad institute
bwb
cardiovascular disease
cindy perettie
colorectal cancer
crispr
dan ollendorf
david liu
detroit blog main
detroit top stories
drugs
editas medicine
eisai
europe blog main
What
medicine
3
×
patients
3
×
fda
market
ago
alnylam
approve
awaits
benefiting
biological
boston
cancer
coming
crossed
decades
decision
diagnostics
discovered
drug
eisai
fingers
flags
friday
glimcher
groundbreaking
headline
higher
historic
incidence
keynote
laurie
lorcaserin
loss
marketing
post
precision
promise
pulls
risks
rna
Language
unset
Current search:
xconomy.com
×
medicine
×
patients
×
" new york blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision